http://www.reportlinker.com/p0887610/Bone-Metabolism-Therapeutics-Market-to-2018---Hyperparathyroidism-Sector-to-Decline-in-the-Absence-of-New-Product-Launches-and ...

Dr. Reddy’s is launching doxercalciferol injection, in 4 mcg/2 mL multidose vials. The product is the generic of Sanofi-Aventis’ Hectorol (doxercalciferol) injection 4 mcg/2 mL (2 mcg/mL) ...

Lupin’s Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vial is the generic version of Genzyme’s Hectorol Injection. It is indicated for the treatment of secondary hyperparathyroidism in ...

PRINCETON, N.J. — Sandoz announced the launch of doxercalciferol injection vials, the first generic version of Genzyme’s Hectorol. Doxercalciferol injection vials are used for the treatment of ...

Law360 (June 14, 2010, 1:27 PM EDT) -- Genzyme Corp. has filed a patent infringement suit against Anchen Pharmaceuticals Inc. in an effort to block a generic version of renal disease treatment ...

WILMINGTON, Del., May 25 (Reuters) - Genzyme Corp has sued Sandoz Inc, accusing it of infringing the patent for its Hectorol drug which is approved for controlling hormone production in patients with ...

Dr Reddy’s Laboratories Ltd has launched Doxercalciferol injection in the US market. It is the therapeutic generic equivalent of Hectorol (doxercalciferol) injection approved by the US Food and Drug ...

Dr. Reddy’s Laboratories (DRL) has launched Doxercalciferol injection, 4 mcg/2 mL (2 mcg/mL) multiple-dose vials, in the U.S. market. A therapeutic generic equivalent of Hectorol (doxercalciferol) ...

New Report Added in ResearchMoz Reports Database Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic ...